KRAS and cancer: Our results build on these previous findings and further underscore the poor prognosis and high unmet medical need that exists in patients with aNSCLC with co-occurring mutations in STK11 and KEAP1, with either KRAS WT cancer or KRAS G12C–positive cancer.